FDA Clears Momentis Surgical's Anovo System for Multiport Surgery, Making It the First Robotic Platform to Support Three Surgical Approaches

Momentis Surgical has received FDA 510(k) clearance for the multiport configuration of its Anovo® Surgical System, making it the first robotic platform capable of supporting all three surgical access approaches on a single system:
natural orifice surgery, single-port surgery, and multiport surgery.

The new FDA clearance allows surgeons to perform natural orifice, single-port, and multiport procedures on a single flexible robotic platform, reducing the need for multiple robotic systems and expanding the system's modularity.

This approval enables general surgeons to choose between single-site and multiport approaches for ventral hernia repair, and gives gynecologic surgeons an additional multiport option alongside single-site and transvaginal approaches for benign procedures.

The Anovo platform previously received FDA authorization for single-site and natural orifice transvaginal benign gynecologic procedures, including benign hysterectomy, and more recently for single-site ventral hernia repair, and is now the only robotic surgical platform cleared to support multiple surgical access strategies on a single platform.